Weifang Ruze New Material Co., Ltd.

 

Your Aspiration is Our Commitment

Home
Products
About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
Home ProductsNon Small Cell Lung Cancer Medications

Customer synthesis Non Small Cell Lung Cancer Medications Dacomitinib (PF299804,1110813-31-4)99% assay

Ruze supply good service, thanks.

—— Gaurav

I'm Online Chat Now

Customer synthesis Non Small Cell Lung Cancer Medications Dacomitinib (PF299804,1110813-31-4)99% assay

China Customer synthesis Non Small Cell Lung Cancer Medications Dacomitinib (PF299804,1110813-31-4)99% assay supplier
Customer synthesis Non Small Cell Lung Cancer Medications Dacomitinib (PF299804,1110813-31-4)99% assay supplier Customer synthesis Non Small Cell Lung Cancer Medications Dacomitinib (PF299804,1110813-31-4)99% assay supplier

Large Image :  Customer synthesis Non Small Cell Lung Cancer Medications Dacomitinib (PF299804,1110813-31-4)99% assay

Product Details:

Place of Origin: Weifang,China
Brand Name: RuzE
Model Number: TC-9055

Payment & Shipping Terms:

Minimum Order Quantity: Negotiable
Price: Negotiable
Packaging Details: 100g, 1kg Alumium Foil bag
Delivery Time: 5-10workdays
Payment Terms: L/C, T/T, Western Union, MoneyGram
Supply Ability: 20kg/Month
Contact Now
Detailed Product Description
Product Name: Dacomitinib (PF299804) CAS: 1110813-31-4
MF: C24H25ClFN5O2 MW: 469.9390032
EINECS: -0 Mol File: 1110813-31-4.mol

Weifang Ruze New Material Co.,LTD a China supplier of Dacomitinib (PF299804) (CAS No.:1110813-31-4 ),CAS 1110813-31-4 offers for your requirements of RND, evaluation, pilots and commercial along with supportive technical package required for evaluation.

 

Customer synthesis Non Small Cell Lung Cancer Medications Dacomitinib (PF299804,1110813-31-4)99% assay

 

Dacomitinib (PF299804,1110813-31-4)

 

[Product Name]:Dacomitinib (PF299804)

[Synonyms]:PF-299804 (Dacomitinib,PF-00299804);

[CAS]:1110813-31-4

[MF]:C24H25ClFN5O2

[MW]:469.9390032

[Assay]:99%

[Appearance]:white Powder
[Stock]: less than 10kg

[Customer Synthesis] : Availabe

[Package]:100g, 500g, 1kg Foil bag/Bottle

[Uses]:PF299804 is a potent, irreversible pan-ErbB inhibitor against ErbB1, ErbB2 and ErbB4 with IC50 of 6 nM, 45.7 nM and 73.7 nM, respectively.


Dacomitinib (PF299804) Chemical Properties


density 1.344
form White solid.
CAS DataBase Reference 1110813-31-4

Safety Information


HS Code 29335990

Dacomitinib (PF299804) Usage And Synthesis


Description Dacomitinib is a selective and irreversible inhibitor of EGFR. It is a drug candidate for the treatment of non-small cell lung carcinoma. It is current under the Phase III clinical trials. It also shows potential for the treatment of HER-2 amplified breast cancer cells lines that are resistant to trastuzumab and lapatinib.
Biological activity Dacomitibib (Dacomitinib, PF299804) is an effective and irreversible pan-ErbB inhibitor that is most effective in EGFR, with an IC50 of 6 nM. It is also highly effective in NSCLCs that carries EGFR or ERBB2 mutants (against Gefitinib) and EGFR T790M mutant. Phase 2.
Dacomitinib is taken orally once-daily. It is an irreversible inhibitor of HER-1 (EGFR), HER-2 and HER-4 tyrosine kinases. Dacomitinib targets multiple receptors of the HER pathway, whereas currently marketed HER-1 (EGFR) inhibitors for non-small cell lung cancer (NSCLC) target only one receptor in this pathway,developed by Pfizer.
Clinical Study Dacomitinib has advanced to several Phase III clinical trials. The results of the first trials were disappointing, with a failure to meet the study goals, Additional Phase III trials are ongoing.
Clinical evaluation of dacomitinib is ongoing in a number of clinical trials in patients with advanced NSCLC across lines of therapies and a range of histologies and molecular subtypes, such as EGFR and KRAS status.
Additionally, there is an ongoing clinical trial evaluating dacomitinib in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).
References Ellis, Peter M,, et al. "Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. " Lancet Oncology 15.12(2014):1379.
Kalous, O, et al. "Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib. " Molecular Cancer Therapeutics11.9(2012):1978.
https://en.wikipedia.org/wiki/Dacomitinib
Uses PF299804 is a potent, irreversible pan-ErbB inhibitor against ErbB1, ErbB2 and ErbB4 with IC50 of 6 nM, 45.7 nM and 73.7 nM, respectively.
Definition ChEBI: A member of the class of quinazolines that is 7-methoxyquinazoline-4,6-diamine in which the amino group at position 4 is substituted by a 3-chloro-4-fluorophenyl group and the amino group at position 6 is substituted by an (E)-4-(piperidin 1-yl)but-2-enoyl group.

 

 

 

 

Customer synthesis Non Small Cell Lung Cancer Medications Dacomitinib (PF299804,1110813-31-4)99% assayCustomer synthesis Non Small Cell Lung Cancer Medications Dacomitinib (PF299804,1110813-31-4)99% assay

Customer synthesis Non Small Cell Lung Cancer Medications Dacomitinib (PF299804,1110813-31-4)99% assay

Customer synthesis Non Small Cell Lung Cancer Medications Dacomitinib (PF299804,1110813-31-4)99% assay

Customer synthesis Non Small Cell Lung Cancer Medications Dacomitinib (PF299804,1110813-31-4)99% assayCustomer synthesis Non Small Cell Lung Cancer Medications Dacomitinib (PF299804,1110813-31-4)99% assay

Weifang Ruze New Material Co.,LTD supply free sample and datebase on Dacomitinib (PF299804) (CAS No.:1110813-31-4 ), if you want futher information about Dacomitinib (PF299804) (CAS No.:1110813-31-4 ), please feel free to contract us.

 

Contact Details
Weifang Ruze New Material Co., Ltd.

Contact Person: Ruze02

Send your inquiry directly to us (0 / 3000)